| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8727493 | Gastroenterology | 2017 | 41 Pages |
Abstract
In a multicenter prospective study of patients with hepatitis C virus-associated cirrhosis, an SVR to all-oral therapy significantly reduced HVPG, compared with before treatment. Nevertheless, CSPH persists in most patients despite SVR, indicating persistent risk of decompensation. In this population, changes in LSM do not correlate with HVPG and cut-off values are not reliable in ruling out CSPH after SVR.
Keywords
DAAHVPGCSPHmPAPSofosbuvirRBVAUROCSOFIQRNSBBSVRCPTHCCliver stiffness measurementclinically significant portal hypertensionLiver diseasedirect-acting antiviralsAntiviral therapyRibavirinLSMHepatic venous pressure gradientmean pulmonary arterial pressureinterquartile rangePulmonary vascular resistanceHepatitis C virusHCVsustained virological responseoverall responsePulmonary hypertensionPortal hypertensionHepatocellular carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Sabela Lens, Edilmar Alvarado-Tapias, Zoe Mariño, MarÃa-Carlota Londoño, Elba LLop, Javier Martinez, Jose Ignacio Fortea, LuÃs Ibañez, Xavier Ariza, Anna Baiges, Adolfo Gallego, Rafael Bañares, Angela Puente, AgustÃn Albillos, Jose LuÃs Calleja,